Work

Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors

Year: 2020

Type: article

Study design: Clinical Trial

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(20)31211-9

Authors: K. Papadopoulos, M. Sharma, E. Hamilton, D. Richardson, B. Bashir, G. Hodgson, N. Ke, Q. Kang-Fortner, L. Zhou, W. Zamboni, H. Jolin, C. Madigan, M. Kelly, D. Roth

Institutions: South Texas Accelerated Research Therapeutics, Sarah Cannon, Tennessee Oncology, OU Health Stephenson Cancer Center, Thomas Jefferson University Hospital, Syros Pharmaceuticals (United States)

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W3095928672

FWCI: 0.281

Cites:

Cited by: 4

Related to: 10